Abstract:Objective: Single-cell RNA-seq (scRNA-seq) analysis has been widely applied in oncology research for biomarker discovery. Although droplet-based methods are commonly used for such studies owing to their high throughput, they still miss important insights due to their lack of full-length transcript coverage. While full-length methods are available, to date, they have not been able to meet the throughput demands of many researchers. Moreover, both droplet and full-length scRNA-seq methods do not currently provide adequate readouts for non-coding genes, thereby limiting investigation of gene regulatory networks to protein coding genes. To close these gaps, we have developed a new high-throughput full-length scRNA-seq workflow that comprehensively profiles both protein-coding and non-coding genes in up to 60,000 cells within two days. Methods: Our new high-throughput workflow uses two rounds of combinatorial indexing, starting with a 96-well plate format for the first barcoding step followed by an automated second barcoding step in a 5,184-nanowell chip using an automated nanodispensing system. Initial testing demonstrated that our method could handle up to 60,000 cells without generating significant levels of doublets due to barcode collisions. To further illustrate the capacity of the new scRNA-seq approach, we profiled a total of approximately 11,000 isogenic A549 cells that either express WT TP53 or are TP53 null. In addition, both isogenic cell lines were treated with epigenetic therapy or mock treatment. Libraries were generated and sequenced using an Illumina® NextSeq®2000 sequencer. The sequencing data was then analyzed to define differential gene expression for both protein-coding and non-coding transcripts as a function of TP53 genotype and treatment condition, using CogentTM NGS software. Results: Preliminary analysis showed that, on average, approximately 11,000 genes and 40,000 transcripts were detected per single cell at a read depth of 100,000 reads per cell. UMAP-based clustering confidently separated the cells according to their genotypes and treatment conditions using either protein-coding genes or non-coding genes. Furthermore, differential expression analysis identified both protein-coding and non-coding transcripts with significant expression differences, underscoring biological significance. Conclusion: Our new high-throughput full-length scRNA workflow enables preparation of high-quality full-length RNA-seq libraries for up to 60,000 cells with only two rounds of barcoding and shows high sensitivity and specificity in gene/transcript detection and quantification. The technology significantly improves the ability to identify new biomarkers by enabling comprehensive profiling of both protein-coding and non-coding full length transcripts. Citation Format: Peng Xu, Joseph Liu, Yana Ryan, Kazuo Tori, Xuan Li, Hima Anbunathan, Mike Covington, Tomoya Uchiyama, Mohammad Fallahi, Xuan Qu, Xiaoyun Xing, Ting Wang, Bryan Bell, Shuwen Chen, Yue Yun, Andrew Farmer. A novel, high-throughput full-length scRNA-seq workflow for improved biomarker discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 316.

An optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification

Abstract 7418: LongFuse: Detecting gene fusion transcripts from high throughput long-read single cell RNA sequencing data

LongGF: Computational Algorithm and Software Tool for Fast and Accurate Detection of Gene Fusions by Long-Read Transcriptome Sequencing

CTAT-LR-fusion: accurate fusion transcript identification from long and short read isoform sequencing at bulk or single cell resolution

SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA

Enhanced Detection of Novel Low‐Frequency Gene Fusions via High‐Yield Ligation and Multiplexed Enrichment Sequencing

Comprehensive Evaluation of Fusion Transcript Detection Algorithms and a Meta-Caller to Combine Top Performing Methods in Paired-End RNA-seq Data.

FusionQ: a Novel Approach for Gene Fusion Detection and Quantification from Paired-End RNA-Seq.

1148P Identification and Validation of RET Fusions in Lung Adenocarcinoma Through DNA and RNA Sequencing

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Fusion Transcripts And Transcribed Retrotransposed Loci Discovered Through Comprehensive Transcriptome Analysis Using Paired-End Ditags (Pets)

Abstract 221: Development of a rapid, highly sensitive cell-free RNA NGS assay for the detection of gene fusion and splicing variants in cancers

Abstract 321: Optimized RNA Seq library preparation for fusion calling from FFPE samples

Identification of Cancer Gene Fusions Based on Advanced Analysis of the Human Genome or Transcriptome

Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction.

SOAPfuse: an Algorithm for Identifying Fusion Transcripts from Paired-End RNA-Seq Data

Abstract 315: Cost-effective, comprehensive detection of gene fusions from DNA and RNA using the UG100 sequencer

Abstract 316: A novel, high-throughput full-length scRNA-seq workflow for improved biomarker discovery

A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions

Abstract 465: Development and validation of a targeted RNA-Seq assay for gene fusion detection and expression quantification in FFPE samples

Transcriptome Sequencing to Detect Gene Fusions in Cancer